South Easton, MA -- (ReleaseWire) -- 10/10/2017 -- Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that multiple presentations have highlighted features and benefits of the Company's recently-released, next-generation Barocycler 2320EXTREME instrument (the "Barocycler 2320EXT") at scientific meetings in Germany, Poland, and Ireland over the past 30 days.

SCIEX Sponsored Mass Spectrometry Seminar (Munich, Germany)

SCIEX, a global leader in life sciences analytical technologies, and a co-marketing partner of PBI, organized an all-day seminar focused on the latest applications of mass spectrometry in digital biobanking. Attendees included SCIEX users and key scientific and clinical opinion leaders from Germany and other European countries. Several speakers discussed the use and advantages of PBI's Barocycler 2320EXT in their studies in combination with SCIEX mass spectrometers.

Dr. Alexander Lazarev, Vice President of R&D at PBI, was one of the nine invited speakers at the seminar. Dr. Lazarev said, "It was indeed a privilege to be included in this agenda with so many prominent proteomic scientists. It was gratifying to hear multiple presenters discuss the Barocycler 2320EXT as an essential part of their proteomic workflow. The questions and attention on PCT throughout the seminar made it clear that our new, CE-marked Barocycler 2320EXT is poised for an exciting future throughout Europe."

55th European High Pressure Research Group (Poznan, Poland)

Attended by many of Europe's most influential high-pressure scientists and engineers, the 55thEHPRG brought together leading experts from 26 countries active in the field of high-pressure research for intensive discussions on common interests, problems, and possibilities. High-pressure research is a rapidly growing discipline, yielding fascinating new capabilities and exciting results across many scientific fields, biotechnology in particular.

At a session dedicated to high-pressure biophysics, Professor Hans Robert Kalbitzer, from the University of Regensburg (Germany), highlighted the use and importance of PBI's HUB440 instrument for automated, high pressure nuclear magnetic resonance ("NMR") studies that aid in drug design and development.

PBI's Dr. Alexander Lazarev, also a speaker at EHPRG 2017, presented data generated in PBI's laboratories showing that under elevated pressure and temperature, certain enzymatic processes could be accelerated up to twenty times, positioning them to potentially play key enabling roles in biomarker discovery and biopharmaceutical quality control.

16th Human Proteome Organization (HUPO) World Congress (Dublin, Ireland)

HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques, and training to better understand human disease. Joseph R. Biden Jr., the 47th Vice President of the United States, delivered a keynote address at the Global Leadership Gala Dinner on the theme of "International Cooperation in the Fight against Cancer."

Dr. Tiannan Guo, MD, Ph.D., of the Westlake Institute for Advanced Study (China), presented data on the use and enabling impact of PCT-SWATH for the proteomic analysis of formalin-fixed, paraffin-embedded (FFPE) tissue samples.

Dr. Vera Gross, Director of Applications Development at PBI, presented data highlighting a potential use of high pressure for rapid inactivation of endogenous enzymes in tissue samples to preserve integrity of fragile protein molecules during subsequent sample preparation workup.

Dr. Nathan Lawrence, Vice President of Marketing and Sales at PBI, commented, "It is estimated that there are more than one billion FFPE archival tissue samples in the world, collected over a span of many decades. Complete clinical histories for such samples are often available, including such important data as disease progression and outcome, medications taken, and symptoms. More effective analyses of such samples, enabled by methods such as PCT, is expected to result in a bonanza of new and important biomarker discoveries. These discoveries open pivotal opportunities for development of new drugs, therapies, and disease-prevention strategies.

Dr. Lawrence continued, "Data that Dr. Guo presented offer exciting validations for the value of PCT. We are pleased that PCT was a vital part of his work plan. We continue to work towards our goal of making PCT available for the work plans of thousands of other scientists as well."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented, scalable, high-efficiency Ultra Shear Technology ("UST") to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing, FDA-approved, high-pressure processing ("HPP") technologies.

Forward-Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:
Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D., VP of Marketing and Sales 508-230-1828 (T)

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Compelling Advantages of the Company’s Patented PCT Platform Highlighted in Two Different Mass Spectrometry User Meetings on Day One

South Easton, MA -- (ReleaseWire) -- 06/06/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIOD) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that the Company's patented PCT platform will be featured in multiple presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), being held from June 4-8, 2017 in Indianapolis, IN.

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: "It is encouraging that in less than one year from the initial shipment of the Barocycler 2320EXT, the advantages of this next-generation PCT-based instrument will be highlighted in multiple presentations by well-respected scientific groups from around the world. These groups include researchers from such noteworthy institutions/companies as the U.S. Food and Drug Administration, Novo Nordisk A/S (Denmark), SCIEX (U.S. and Australia), ETH Zurich (Switzerland), the University of Cologne (Germany), and the Inova Schar Cancer Institute (U.S.).

Dr. Lawrence continued: "Dr. Thomas Conrads, a nationally-acclaimed protein chemist, is the Associate Director of Scientific Technologies at the Inova Schar Cancer Institute. Dr. Conrads and his group were invited to participate in the SCIEX and ThermoFisher Scientific User Meetings on June 4^th. During their presentations, they highlighted the use of the Barocycler 2320EXT for the digestion of tumor and other samples to be analyzed by their group as part of discovery proteomics for the APOLLO Consortium of the Cancer Moonshot program."

"Proteins comprise most of the biomarkers that are measured to detect cancers, they constitute the antigens that drive immune response and the inter- and intra-cellular communications, and they are the drug targets for nearly every targeted therapy that is being evaluated in cancer trials today," commented Dr. Conrads. "We believe that a combined systems biology view of the tumor microenvironment that orients cancer studies back to the functional proteome, phosphoproteome, and biochemistry of the cell will be essential to delivering on the promise of the Cancer Moonshot program."

Dr. Conrads continued: "Standardized, reproducible, high quality preparation of samples to be analyzed is critical to the success of transformative research studies. We spent many months investigating multiple aspects of PCT-enhanced protein extraction and digestion. We subsequently concluded that PCT was an enabling tool that met our high standards for critical sample preparation. We also concluded that the PCT platform could make profiling of our laser micro-dissected tumor tissue samples possible at the throughput required by the APOLLO Consortium of the Cancer Moonshot program."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "The ASMS Conference is one of the largest annual meetings of mass spectrometry professionals worldwide. At the 2016 ASMS Conference, we unveiled the newest addition to our PCT-based instrument line, the Barocycler 2320EXT. Designed with a number of new and enhanced features and benefits to enable scientists better access to biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, we believe the 2320EXT offers the potential to result in new biological insights and discoveries, and rapid growth for PBI."

Mr. Schumacher continued: "In February 2017, the Barocycler 2320EXT gained CE Mark approval, enabling it to be marketed throughout all 31 countries in the European Economic Area. In March 2017, the 2320EXT received the 2017 North American Excellence Award for 'Best New Instrument for Sample Preparation' by Corporate America News, a leading business publication. The Barocycler 2320EXT has become the centerpiece of our co-marketing agreement with global life sciences analytical technologies leader SCIEX. We believe it will continue to find a significant role in transformative research efforts worldwide, such as the Cancer Moonshot program."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIOD) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 270 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

SOURCE: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Dr. Aebersold Presented Two Karger Medal Lectures Describing State-of-the-Art Proteomics Research: Pressure BioSciences’ Patented PCT Platform for Sample Preparation – a Critical Step in Scientific Analysis - was Discussed in Both Presentations

South Easton, MA -- (ReleaseWire) -- 06/05/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that Dr. Ruedi Aebersold recently received the prestigious Karger Medal from the Barnett Institute of Chemical & Biological Analysis at Northeastern University in Boston MA. The Medal is awarded biennially to honor Dr. Barry Karger, the founding director of the Barnett Institute. The award recognizes an individual who has significantly contributed to the development of new bioanalytical methods.

As part of the award ceremony, Dr. Aebersold presented a seminar open to the public entitled "The Proteome in Context" and a second technical seminar for the Boston scientific community entitled "SWATH-MS: Principles, Current State and New Developments" which highlighted his research in proteomics. Proteomics is the study of the entire set of proteins produced by healthy and diseased cells. Both lectures included slides describing his use of PBI's novel, award winning, next-generation Barocycler 2320EXTREME for proteomic sample preparation in biomarker discovery and other transformative research applications.

Dr. Aebersold is Professor of Systems Biology at the Institute of Molecular Systems Biology (IMSB) in the Department of Biology at the ETH Zurich, in Switzerland. He is a world-renowned scientist, and a pioneer in the field of proteomics. He is best known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics. Dr. Aebersold is the recipient of numerous awards and honors for his work in proteomics. In 2015, he was named the most influential person in the world of analytical science by the Analytical Scientist group.

In his lectures, Dr. Aebersold emphasized the importance of high quality sample preparation for the elucidation of the proteome and the importance of assay reproducibility to validate comparisons of healthy cells to diseased cells. Dr. Aebersold also included the important role that PBI's PCT platform plays in his research. He stated: "Not only do we need to consider the method of analyzing the proteome, we must also recognize that the method of sample preparation used for extraction and digestion of proteins is equally important to achieve a high degree of reproducibility of research results."

Dr. Aebersold serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics. In 2015, Dr. Aebersold and Dr. Tiannan Guo collaborated with PBI scientists and engineers to develop PCT-SWATH, a sample preparation and analysis method that combines PBI's PCT-based sample preparation platform with SCIEX's SWATH-MS-based proteomics workflow. PCTSWATH is also notably employed by ProCan, a cancer research initiative at the Children's Medical Research Institute, near Sydney Australia, which is also an NCI Cancer Moonshot collaborator.

Dr. Nate Lawrence, Vice President of Marketing and Sales at PBI commented: "We are delighted that Dr. Aebersold has again been recognized for his groundbreaking research in proteomics. We are honored to be both his colleague and collaborator in the development of instrumentation and methods essential in the preparation of samples for the discovery of protein biomarkers and other important applications. We look forward to working with Professor Aebersold and his team for years to come."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 270 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

SOURCE: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on Monday, June 5, 2017

South Easton, MA -- (ReleaseWire) -- 06/02/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" or the "Company") today announced a one-for-thirty reverse split of its common stock effective as of Monday, June 5, 2017. The shares underlying the Company's outstanding convertible securities will also be adjusted accordingly.

The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $4.00 minimum bid price requirement for initial listing on the NASDAQ Capital Market. As a result of the reverse stock split, every thirty shares of the Company's common stock issued and outstanding prior to the opening of trading on June 5, 2017 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.01. No fractional shares will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive an additional fraction of a share of common stock to round up to the next whole share.

Trading of the Company's common stock on the OTCQB will continue, on a split-adjusted basis, with the opening of the markets on Monday, June 5, 2017, under new CUSIP number 74112E208. Shares of the Company's common stock will continue to trade under the symbol "PBIO". Immediately subsequent to the reverse stock split, there will be approximately 1,055,232 shares of the Company's common stock issued and outstanding.

The Company has retained its transfer agent, Computershare Trust Company, N.A. ("Computershare"), to act as its exchange agent for the reverse stock split. Computershare will provide shareholders of record as of the effective date instructions for the exchange of their certificates. Shareholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.

For more information regarding the Company's reverse stock split, please refer to the proxy statement filed by the Company with the Securities and Exchange Commission on Schedule 14A on November 15, 2016.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Total revenue, products & services revenue, consumable sales, & gross margins all increased while operating loss decreased, quarter-over-quarter. CFO Hire, CE Marking Achievement, Sales & Marketing Expansion expected to help drive revenue, expand customer base, and increase shareholder value throughout FY2017. Investor Conference Call scheduled for Tuesday, May 16, 2017 at 4:30 PM EDT.

South Easton, MA -- (ReleaseWire) -- 05/16/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced financial results for the first quarter of 2017, provided a business update, and offered limited guidance on its growth plan for FY2017.

Financial Results: Q1 2017 vs. Q1 2016

Products and services revenue increased 16% to $525,998 for Q1 2017 as compared to $454,350 for Q1 2016. This increase was primarily attributable to an increase of 19% in the sale of instrument systems, from $332,016 in Q1 2016 to $396,095 in the same quarter of 2017. Sales of consumables also increased during these same periods, from $44,234 in Q1 2016 to $63,264 in Q1 2017, an increase of 43%. Grant revenue decreased from $56,128 in Q1 2016 to $25,359 in Q1 2017. We believe grant revenue will increase over the remaining quarters in 2017.

Despite this decrease in grant revenue, total revenue increased to $551,357 for the three months ended March 31, 2017 as compared to $510,478 during the three months ended March 31, 2016, an increase of $40,878 or 8%. This increase was attributable to increases in the sales of our products and services.

Operating loss decreased to $999,103 in Q1 2017 from $1,045,945 for the same period in 2016, a reduction of $46,842 or 4%. This decrease was primarily due to reduced R&D expenses combined with increased sales of product and services.

Loss per common share – basic and diluted – was $0.18 for Q1 2017 compared to a loss per common share of $0.26 for the same period in 2016.

Financial and Operational Highlights: Q1 2017

February 2, 2017. PBI announced it had achieved CE Marking for the Barocycler 2320EXTREME (the "Barocycler 2320EXT"), the Company's recently released, next-generation PCT-based sample preparation instrument. With the achievement of CE Marking, the Company can now market and sell the Barocycler 2320EXT in all 31 countries comprising the European Economic Area.

March 1, 2017. The Company announced that the Barocycler 2320EXT had been named the "Best New Instrument for Sample Preparation 2017" by Corporate America News as part of the publication's 2017 North American Excellence Awards.

March 23, 2017. The Company announced it had significantly bolstered its marketing and sales capabilities by contracting with EKG Sales Associates, a lead generation company, and by hiring two of the Company's planned four field sales directors.

Mr. Joseph L. Damasio, Jr., VP of Finance and CFO, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services. We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss. We believe the financial results of the first quarter 2017 have set us up well to significantly drive revenue and business growth for the rest of the fiscal 2017 year, and beyond."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Although pleased with the financial results of the first quarter, we are even more pleased with our operational accomplishments. During the first quarter, we made significant progress on our clearly-defined 2017 goals to (i) develop a clear and sustainable path to profitability and financial self-sufficiency; (ii) enhance and expand our current sales and marketing capabilities with the hiring of a minimum of four field sales directors, plus an external lead-generation service and internal operational personnel; and (iii) achieve an up-list to the NASDAQ Stock Exchange by or before the end of the 2017 second quarter. We believe that continued progress on or the achievement of these goals will position PBI to be a stronger, more valuable company, which in turn should increase shareholder value, which is our ultimate goal."

Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, May 16, 2017. To attend this teleconference via telephone, Dial-in: 877-407-8031 (North America), 201-689-8031 (International). Verbal Passcode: PBIO First Quarter 2017 Financial Call. Replay Number 877-481-4010; 919-882-2331 (International). Replay ID Number: 10404. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed nearly 300 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should  not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the year ended December 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 05/16/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2017 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay approximately one day after the call (by telephone or via a link on the Company's website).

The teleconference will include a Company presentation followed by a question & answer period.

Date: Tuesday, May 16, 2017  
Time: 4:30 PM Eastern Daylight Time (EDT)

To attend this teleconference live by telephone:

Dial-in: 877-407-8031 (North America); 201-689-8031 (International)

Verbal Passcode (to be given to the operator): PBIO First Quarter 2017 Financial Call

For those unable to participate in the live teleconference, a replay will be available beginning on Wednesday, May 17, 2017. The replay will be accessible both by telephone and through the Company's website for 30 days.

Replay Number: 877-481-4010 (North America); 919-882-2331 (International) Replay ID Number: 10404

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed nearly 300 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contact:
Richard T. Schumacher, President & CEO
508-230-1828

SOURCE: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 03/23/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that it has significantly bolstered its marketing and sales capabilities by contracting with well-known and highly regarded EKG Sales Associates, and by hiring two of its planned four additional field sales directors. For the past few years, the Company's selling efforts have relied on two part-time field sales directors in the U.S. and several distribution partners internationally.

EKG Sales Associates ("EKG") is a well-known life sciences lead generation service. EKG has spent over 20 years developing a contact database with over 50,000 scientists and other individuals from the life sciences area, some of whom are key decision makers. These contacts are from academia, government, pharma, and biotech. EKG Sales Associates has maintained a regular dialogue with these contacts about laboratory equipment and associated consumables over many years.

Dr. Nate Lawrence, VP of Marketing and Sales at PBI, said: "EKG came highly recommended from several industry colleagues, who said they were among the best at generating real, viable leads. We consequently hired them on a three-month trial basis. Due to the quality and number of leads received during the trial period, we are now working on a contract extension that will take us to 2018."

Ms. Mary Kay Walsh, President of EKG, said: "We look forward to extending our relationship with Pressure BioSciences. They have a unique technology platform in PCT. Their instrument and consumables product lines have received a great response from scientists within our contact network, especially their recently released, award-winning Barocycler 2320EXTREME. Our team looks forward to the opportunity of helping to increase PBI's share of the vital sample preparation market across all of the U.S. and Canada into 2018."

In addition to engaging EKG, PBI has also hired two field sales directors over the past two weeks. Ms. Rajni Kareer will serve as the Company's Sales Director covering all of the west coast of the U.S. The other Sales Director just hired – Mr. Nicholas Cobb – will cover upstate New York, northern New England, and all of eastern Canada. He will also have responsibility for field service throughout the U.S. and Canada. Both hires have a strong background in selling capital equipment to research laboratories, including spectrometers and HPLC equipment, as well as laboratory consumables.

Ms. Roxana McCloskey, Director of Marketing and Sales for North America, said: "We are delighted to have Rajni and Nick join our rapidly-growing sales team. Both attended the 2017 U.S. Human Proteome Organization Conference in San Diego this week, working in our exhibit booth and meeting with scientists, some of whom already use PCT in their research studies. Their deep experience allowed them to 'hit the ground running'. We believe they will be highly successful field sales directors for PBI."

Ms. McCloskey continued: "We are excited with the hires of EKG and our two new field sales directors, but there is still much to do to complete our plan to build a viable, experienced, and successful marketing and sales team at PBI. We are committed to the immediate hire of at least two additional field sales directors, one each for the mid-west and east coast regions. We have interviewed a number of strong candidates and believe we will be in a position to fill these two open territories with superb candidates in short order. Once we have our initial team of four field sales directors, and a strong source of well-qualified leads from our EKG colleagues, we believe we will be well-positioned to pursue our aggressive sales goal for the remainder of 2017."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Forward Looking Statements:
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the year ended December 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:
Richard T. Schumacher, President & CEO
Nathan P. Lawrence, Ph.D., VP of Sales and Marketing
(T) 508-230-1828

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 03/23/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2016, provided a business update, and offered limited guidance for FY2017.
 
Financial Results: Q4 2016 vs. Q4 2015
 
Products and services revenue was $365,262 in the fourth quarter of 2016 compared to $235,600 in the same quarter of 2015, a 55% increase. Sales of consumables were $50,054 for the fourth quarter ended December 31, 2016 compared to $29,521 for the same period in 2015, an increase of 70%. Grant revenue for Q4 2016 was $54,449 compared to $128,519 for the same period in 2015.
 
Total revenue for the fourth quarter ended December 31, 2016 was $419,711 compared to $364,119 for the same period in 2015, a 15% increase. This increase was due to products and services sales growth.
 
Operating loss for Q4 2016 was $1,177,205 compared to a loss of $935,746 for the same period in 2015. This increase was due primarily to inventory valuations and increases in marketing/IR activities, off-set by an increase in total revenue.
 
Income per common share – basic– was $0.10 for Q4 2016 compared to a loss per common share of $0.19 for the same period in 2015. Income per common share – diluted– was $0.03 for Q4 2016 compared to a loss per common share of $0.19 for the same period in 2015.
 
Financial Results: FY2016 vs. FY2015
 
Products and services revenue was $1,794,749 in the year ended December 31, 2016 compared with $1,409,991 in the year ended December 31, 2015, a 27% increase. Sales of consumables were $199,873 for the year ended December 31, 2016 compared to $146,408 for the same period in 2015, an increase of $53,465 or 37%. Grant revenue for fiscal year 2016 was $181,738 compared to $387,700 for the 2015 fiscal year.
 
Total revenue for the fiscal year ended December 31, 2016 was $1,976,487 compared to $1,797,691 for the same period in 2015, a 10% increase. This increase was due to products and services sales growth.
 
Operating loss for the year ended December 31, 2016 was $3,735,653 compared to a loss of $3,565,182 for the same period in 2015. This increase in operating loss was due primarily to increases in R&D, Sales and Marketing, and IR expenses, offset to a certain extent by an increase in total revenue.
 
Loss per common share – basic and diluted – was $0.10 for the year ended December 31, 2016 and $0.36 for the same period in 2015.
 
Financial and Operational Highlights: FY2016 & Q1 2017

- January 2016: SCIEX, a global life sciences leader and subsidiary of Danaher Corp, announced a co-marketing agreement with PBI to improve protein quantification in complex samples.

- February: SCIEX and Children's Medical Research Institute (Sydney, Australia) announced a partnership to advance the promise of precision medicine and stated they would benefit from SCIEX's collaboration with PBI and our PCT platform for increased protein quantitation and reproducibility.

- March: PBI participated in a SCIEX workshop on new innovations in industrialized proteomics, marking the first time the two companies had presented together under their co-marketing agreement.

- Q1 2016: $1.4M was received in a private placement of fixed-rate convertible debentures, bringing the total raised in our $5M PIPE to an over-subscribed $6.3M. All five PBI Board members participated.

- April: PBI was added to the high-performing Richmond Club Index.

- June: Scientists from six separate research groups made presentations at the American Association for Mass Spectrometry Annual Meeting on the compelling advantages of the PCT Platform.

- July: We announced the initial shipment of the next-generation Barocycler 2320EXTREME to the Australian cancer research group ProCan, a collaborator in the U.S.'s Cancer Moonshot initiative.

- September: PBI was invited, along with SCIEX, CMRI, Institute of Molecular Systems Biology (Zurich, CH), Beckman-Coulter, Ilumina, and Next-Bio to present at the Gala Opening of the ProCan cancer research center.

- October: We announced the close of a $2M line-of-credit under favorable terms to PBI shareholders.

- February 2017: We announced CE Marking for our new, next-generation Barocycler 2320EXTREME, giving us access to 31 countries in Europe that require the CE Mark prior to product commercialization in Europe.

- March: The Barocycler 2320EXTREME received the 2017 North American Excellence Award for "Best New Instrument for Sample Preparation" from Corporate America News, with a subscription list of over 135,000.
 
Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017. These accomplishments have let us enter the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; important additions to our hard-working and talented staff; a larger customer base; and an expanded and enhanced sales and marketing capability."
 
Mr. Schumacher continued: "Our near-term goals are clear, focused, and attainable in 2017. We believe their achievement will subsequently position PBI to be a stronger, more valuable company. These goals include: (i) an up-list to the NASDAQ stock market in Q2 2017, (ii) measureable progress in completing and implementing a sound roadmap toward financial selfsufficiency and future growth and prosperity, (iii) continuation of the current expansion of our sales and marketing capabilities, and our reach into new countries, investigators, and fields-of-use; and (iv) a focus on sales, sales, and sales."
 
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCMKTS:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.
 
Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Wednesday, March 22, 2017. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBIO Fourth Quarter and Fiscal Year 2016 Financial Call, ID 10291. Replay Number (877) 481-4010; (919) 882-2331 (International). Teleconference Replay Available for 30 days.
 
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the year ended December 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 03/01/2017 -- Pressure BioSciences, Inc. (OTCMKTS:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that its Barocycler 2320EXTREME ("2320EXT") has been named the "Best New Instrument for Sample Preparation 2017" by Corporate America News ("Corp America") as part of the publication's 2017 North American Excellence Awards.

With a subscription list of more than 135,000 business and professional service providers, Corp America is a leading magazine in the U.S business market. The magazine's annual North American Excellence Awards honor companies and individuals who tirelessly work to drive innovation and exhibit true passion for their work.

The award-winning, next-generation Barocycler 2320EXT is the latest addition to PBI's Barocycler family. It is a compact, bench-top instrument offering many advanced features and benefits. These and other additions have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders ("KOLs") worldwide, when preparing protein samples for analysis.

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: "We are honored to have been selected for this prestigious award. It was just eight months ago when we launched this next-generation Barocycler instrument, the 2320EXT. Since then, the instrument has been purchased by key scientists in academic, government, biotech and pharma labs worldwide, including institutions involved in the Cancer Moonshot Initiative. We believe this award affirms the significant potential of the Barocycler 2320EXT."

ProCan, a cancer research initiative located in the Children's Medical Research Institute near Sydney Australia, and a Cancer Moonshot collaborator, purchased three Barocycler 2320EXTs in June 2016. At the time of their purchase, Professor Phil Robinson, co-head of ProCan, said: "Patient tumor samples can be pretty tiny and very heterogeneous, but the use of PCT in sample preparation allows researchers to analyze tissue samples as small as those provided by needle biopsies. So you can use incredibly small amounts of tissue, reliably digest them in a couple of hours, and get large amounts of information with the Barocycler 2320EXT."

Professor Ruedi Aebersold, a world-renowned protein chemist who recently upgraded to the Barocycler 2320EXT, emphasized the importance of sample preparation in the article. Dr.

Aebersold said: "Not only do we need to consider the method of analyzing the proteome, but we must also recognize that the method of sample preparation used to optimize protein extraction & digestion is equally as important."

Dr. Lawrence commented: "It is the support of KOLs like Professors Robinson and Aebersold that we believe helped convince the panel of judges that the Barocycler 2320EXT deserved to win the 2017 North American Excellence Award for Best New Sample Preparation Instrument." PBI President and CEO Richard T. Schumacher was interviewed by the magazine upon selection of the award. In a four-page article, Mr. Schumacher provided an in-depth overview of PBI's patented PCT technology and its unique advantages, the Company's history of innovation and growth, its large market opportunity, additional features and benefits of the 2320EXT, the recent co-marketing agreement with global life sciences leader SCIEX, and his expectations that significant growth is on the horizon.

To view the full article, visit http://www.corporateamericanews.com/2017-north-americanexcellence-awards.com A picture of the award-winning 2320EXT is on the inside front cover of the magazine and the article starts on page 8.

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 02/02/2017 -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that the Company has achieved CE Marking for the Barocycler 2320EXTREME ("2320EXT"), the Company's recently released, next-generation PCT-based sample preparation instrument. PBI is now permitted to begin sales of the Barocycler 2320EXT in the European Economic Area ("EEA").

Since 1985, achievement of CE Marking has been required for products in 24 different categories sold within the European Economic Area ("EEA"). Each product falls under one or more Directives, which determine the specific requirements the product must meet. When the CE Mark is affixed to a product, it signifies the manufacturer's declaration that the product meets all applicable EU safety, health, or environmental requirements. Achieving CE Marking requires substantial cost, time, and effort from the manufacturer, but allows the product to be marketed and move freely throughout all 31 countries in the EEA that require the CE Mark.

The Barocycler 2320EXT is the most recent addition to, and the next generation of, PBI's Barocycler family. It is a compact, bench top instrument offering many features and benefits not found in PBI's earlier Barocycler models, such as data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These and other features have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders ("KOLs") worldwide, when preparing protein samples for analysis.

Among these KOLs is Professor Ruedi Aebersold, a world-renowned protein chemist and Director of the Institute of Molecular Systems Biology in Zurich, Switzerland. Professor Aebersold has been a leading proponent of PBI's PCT-based sample preparation methods prior to proteomic analyses for some time.

When asked to comment on the importance of sample preparation in research studies, and why his laboratory upgraded their sample preparation method to the Barocycler 2320EXT, Professor Aebersold said: "Not only do we need to consider the method of analyzing the proteome, but we must also recognize that the method of sample preparation used for protein extraction & digestion is equally important."

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: "Achievement of CE Marking for the Barocycler 2320EXT is an important next step in our commercialization plans for this powerful and enabling sample preparation instrument, especially since CE Marking is required prior to selling the Barocycler 2320EXT to the large and potentially lucrative biopharmaceutical market in Europe. We recently signed agreements with several strong distribution partners in Europe, our SCIEX co-marketing agreement is entering its second year (SCIEX is a global provider of laboratory instrumentation to the life sciences area, with a large presence in Europe), and Professor Ruedi Aebersold - one of the most recognized world leaders in proteomics - recently purchased two Barocycler 2320EXTs. We believe we are well prepared for our upcoming, planned launch of the CE Marked Barocycler 2320EXT in Europe. These are very exciting times for PBI."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use ourproducts in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Contact:
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
508-230-1828 (T)

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Bill Signed Into Law Earlier this Week Offers the Potential to Completely Transform Cancer Research

South Easton, MA -- (ReleaseWire) -- 12/16/2016 -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, today discussed the potential impact on the Company of the $6.3 billion "21st Century Cures Act" that was signed into law earlier this week. The bill contains $1.8 billion earmarked specifically for cancer research (the "Cancer Moonshot" initiative). The Company's PCT sample preparation system is already being featured as an essential technology and used by leading researchers participating in the Cancer Moonshot and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete. This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

Dr. Nate Lawrence, Vice President of Marketing and Sales at PBI, said: "We believe strongly that discovery starts with sample preparation. Consequently, it is critical that cancer researchers have access to cutting-edge instruments, consumables, and other products that will give them the best chance of success, by giving them the best-in-class method or methods to prepare their samples prior to testing."

Dr. Lawrence continued: "Several months ago, we announced the development and commercial release of our next-generation Barocycler instrument. This instrument was designed specifically with the scientific research community in mind. We announced at the time that the first three commercially available PCT systems were purchased by the Children's Medical Research Institute ("CMRI") in Sydney Australia, to be used in the study of as many as 70,000 tumor samples over seven years. CMRI is an official collaborating site to the Cancer Moonshot."

Dr. Lawrence concluded: "We believe that, in many cases, the use of our PCT Sample Preparation System in protein analysis results in higher quality research data when compared to sample preparation with current technologies. This should result in a greater opportunity for discovery, which is one of the most important goals of the Cancer Moonshot initiative."

Mr. Richard T. Schumacher, President and CEO of PBI, said: "We believe the Cancer Moonshot initiative has the potential to completely transform cancer research. We believe our PCT platform will play a critical role in this regard. In an effort to take advantage of this opportunity, we have already taken action to expand our manufacturing and supply capacity, to expand our sales and marketing capabilities, to increase our collaborative programs with key opinion leaders worldwide, and to enhance our PCT platform applications and support. This is a terrific opportunity for PBI and we are completely focused on taking full advantage of it."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 260 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:
Richard T. Schumacher
President & CEO
(508) 230-1828 (T)

Jeffrey N. Peterson
Chairman
(650) 812-8121 (T)

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company Posts Third Consecutive Quarter with Revenues Over $500,000; Products and Services Revenue Sets Record Highs for Quarter and Year-to-Date; Investor Conference Call Scheduled for Wednesday, November 16, 2016 at 4:30 PM EST

South Easton, MA -- (ReleaseWire) -- 11/16/2016 -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced financial results for the third quarter ended September 30, 2016, and provided a business update.

Financial Results: Q3 2016 vs. Q3 2015. Products and services revenue increased to $500,949 for the third quarter of 2016 from $481,452 for the same quarter of 2015. This was a record high for products and services revenue in a quarter and marked the first time that products and services revenue exceeded half a million dollars in a financial quarter. Revenue was driven primarily by the sale of instruments, which also set a record high with $383,789 for the quarter, compared to $340,084 (the previous record) for the same quarter of 2015. Grant revenue decreased to $34,385 for Q3 2016 from $98,882 for the same quarter in the previous year. We expect grant revenue to begin to increase in the fourth quarter of 2016 and continue to increase into 2017. Total revenue decreased to $535,334 in the third quarter 2016 from $580,334 for the third quarter of 2015. This decrease was due to the decrease in grant revenue.

Operating loss for the quarter ended September 30, 2016 was $451,807 compared to a loss of $690,728 for the same period of 2015. Although we continue to carefully control expenditures, this decrease in operating loss was primarily due to credits received from a professional service organization the Company no longer uses. We believe that had these credits not been received, operating loss for Q3 2016 would have been greater than the operating loss for Q3 2015, primarily because of discounts we offered to initial purchasers of our new next-generation Barocycler 2320EXTREME instrument, higher costs experienced in sales and marketing as we began to expand such capabilities, and costs associated with pursuing CE Marking for the new Barocycler 23230EXTREME. A CE Mark is required by dozens of countries in order to sell product in their country.

Net loss per common share was $(0.03) - basic and diluted - for the quarters ended September 30, 2016 and September 30, 2015.

Financial Results: First Nine Months 2016 vs. First Nine Months 2015. Products and services revenue for the first nine months of 2016 increased to $1,429,487 from $1,174,391 for the same period in 2015. This was a record high for the nine-month period, and exceeded the previous record high (2015) by approximately 22%. Revenue was driven primarily by the sale of instruments, which also set a record high for the nine-month period of $1,001,060, compared to $752,444 (the previous record) for the same period in 2015. Grant revenue decreased during the first nine months of 2016 to $127,289 from $259,181 during the same period in 2015. We expect grant revenue to begin to increase in the fourth quarter of 2016 and to continue to increase in 2017. Total revenue increased to a record $1,556,776 for the nine-month period ended September 30, 2016, compared to $1,433,572 during the same period in 2015. We achieved this level of revenue in spite of the significant decrease observed in grant revenue.

Operating loss for the nine month period ended September 30, 2016 was $2,558,448 compared to a loss of $2,629,436 for the same period in 2015. This decrease in operating loss was primarily due to credits received from a former service provider to the Company, as previously described, and by careful control of expenditures.

Net loss per common share (both basic and diluted) was $(0.23) for the nine months ended September 30, 2016 compared to $(0.17) for the same period in 2015.

Business Highlights: Q3 2016

a) Our new ISO-certified contract manufacturer completed the build of four Barocycler 2320EXTREME instrument systems during the quarter. All four were purchased by customers in Germany and Japan.

b) In July, the Children's Medical Research Institute ("CMRI") was named by Vice President Biden as one of four preeminent cancer research centers in Australia to collaborate with the U.S. National Cancer Institute in President Obama's Cancer Moonshot initiative. CMRI purchased the first three commercially-available Barocycler 2320EXTREME instruments.

c) We made measurable progress towards our goal of achieving CE Marking for our new next-generation Barocycler 2320EXTREME instrument before the end of 2016.

d) PBI was invited, along with representatives from SCIEX, CMRI, the Institute of Molecular Systems Biology (Zurich, Switzerland), Beckman-Coulter, Ilumina, and Next-Bio to make presentations at the Gala Opening of The ACRF International Centre for the Proteome of Human Cancer ("ProCan"). ProCan is located in newly renovated laboratory facilities at CMRI near Sydney, Australia.

A short video discussing our new, next-generation Barocycler 2320EXTREME can be found here:
https://www.youtube.com/watch?v=xbO6Lp4VxwU

Near-Term Goals: Fourth Quarter 2016 and Early 2017

a) Continue to implement a sound path toward financial self-sufficiency and future growth and profitability.

b) Drive acceptance and commercialization of the new Barocycler 2320EXTREME.

c) Support and expand our co-marketing program with SCIEX.

d) Significantly expand sales and marketing capabilities.

Mr. Jeffrey N. Peterson, Chairman of the PBI Board, said: "We have recently announced a number of notable achievements that we believe add critical strength and stability to our company as we have concomitantly increased the acceptance and commercial traction of our PCT platform in both the scientific and investment communities worldwide. These include: (i) a co-marketing agreement with SCIEX, a leader in providing important analytical instrumentation to the global life sciences field; (ii) the elimination of nearly $3 million in floorless debt; (iii) the release of our next-generation, PCT-based instrument (the Barocycler 2320EXTREME) and the subsequent sale of the first nine commercially-available units to customers in the US, Europe, Asia, and Australia; (iv) three consecutive quarters with total revenue surpassing half a million dollars each, with strong product sales leading the way; and (v) closing of the sale of $610,000 of our common stock in a PIPE transaction and our recently opened $2,000,000 line-of-credit."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We believe these and other recent successes have positioned us well for continued growth and future profitability. However, much remains to be done. It is important that we continue to build upon these recent successes. In that vein, it is imperative that we expand and enhance our current financial, operational, and technical capabilities, and that we find additional ways to help ensure that our progress is seen and understood by the worldwide financial and investor communities. To that end, we are committed to using funds from the PIPE Financing, Line-of-Credit, and Product Sales to help achieve these very important and timely goals. This may include, among other things, additions to staff, independent agents, distributors, and consultants focused primarily in sales and marketing,

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in bio-therapeutics characterization, soil & plant biology, vaccine development, counter-bioterror applications, and other areas.

Earnings Call

The Company will hold an Earnings Call at 4:30 PM EST on Wednesday, November 16, 2016. To attend this teleconference via telephone, Dial-in: 877-407-8031 (North America), 201-689-8031 (International). Verbal Passcode: PBI Third Quarter 2016 Financial Call. Replay Number 877-481-4010 (North America); 919-882-2331 (International). ID Number 10158. Teleconference Replay Available for 30 days.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the year ended December 31, 2015 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, Twitter, and Investors Hangout: http://investorshangout.com/

Click Here to View Financial Statement

Investor Contacts:
Richard T. Schumacher
President & CEO
508-230-1828 (T)

Jeffrey N. Peterson
Chairman of the Board
650-812-8121 (T)

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Access to Capital will Enable the Company to Increase Its Focus on Growth and Stability

South Easton, MA -- (ReleaseWire) -- 11/03/2016 -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling constant pressure and pressure cycling technology ("PCT")-based sample preparation solutions to the large and growing worldwide life sciences industry, today announced it has closed a $2 million line-of-credit with an accredited investor.

On October 28, 2016, an accredited investor (the "Investor") purchased from Pressure BioSciences Inc., a Promissory Note in the aggregate principal amount of up to $2,000,000 (the "Note") due and payable on the earlier of October 28, 2017 (the "Maturity Date") or on the seventh business day after the closing of a Qualified Offering (as defined in the Note). On the same day, the Company received its initial $250,000 advance pursuant to the Note and issued to the Investor a five-year Common Stock Purchase Warrant (the "First Warrant") to purchase 625,000 shares of the Company's common stock ("Common Stock") at an exercise price equal to $0.40 per share. The Investor is obligated to provide the Company $250,000 advances under the Note, but the Investor is not required to advance more than $250,000 in any individual fifteen (15) day period and no more than $500,000 in the thirty (30) day period immediately following the date of the initial advance. Notwithstanding the fifteen (15) day period limitation, on November 2, 2016, the Company received a second $250,000 advance pursuant to the Note and the Company issued to the Investor the Second Warrant to purchase an additional 625,000 shares of the Common Stock.

The terms of the First and Second Warrants are identical except for the exercise date, issue date, and termination date. Interest on the principal balance of the Note is to be paid in full on the Maturity Date but may be prepaid without penalty. Interest will be assessed between 10% and 18% as more clearly delineated in the Note. The Investor will also receive 100% warrant coverage on the amount borrowed within seven days of each advance, with an exercise price of $0.40 and a term of five years. The Investor will also receive an origination fee of 5% of the amounts borrowed, payable in cash or in-kind.

For more information on these and other terms of the Note and the Common Stock Purchase Warrant, please see the Form 8K filed on November 3, 2016.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We are pleased that a long-term, accredited investor of the Company has offered us the ability to borrow up to $2 million under very favorable terms, including warrants priced significantly above today's market. We believe access to this capital will allow us to increase our focus on the continued expansion of our sales and marketing capabilities, enhancements in infrastructure, improvements in efficiency, and other measures that will help to increase revenue while decreasing costs as we march towards our goal of profitability."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 260 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Visit Investors Hangout For More Information: http://investorshangout.com/

Contact:
Richard T. Schumacher,
President & CEO, PBI
508-230-1828

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

South Easton, MA -- (ReleaseWire) -- 05/26/2016 -- SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a deeper dive into Pressure BioSciences Inc.'s (OTCQB:PBIO) recently filed first quarter 2016 financial results.

Pressure BioSciences, a developer of proprietary laboratory instrumentation and consumables for the $6 billion life sciences sample preparation industry, recently reported first quarter 2016 revenue that jumped 26% year-over-year, which allowed the company to exceed the $500,000 revenue threshold for only the second time in its history. These gains were driven by strong organic growth in the company's instrument and consumable sales that were partially offset by lower grant revenue. In this article, SECFilings.com takes a deeper look at the company's strong first quarter financial results and several upcoming catalysts that investors may want to watch.

To view the SECFilings.com article, click on the link below or copy and paste the address in your browser: www.secfilings.com

About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

For full disclosure please visit: www.secfilings.com

SECFilings.com
Paul Archie
406-862-2242
parchie@secfilings.com
http://secfilings.com/

Source: www.upticknewswire.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Investor Conference Call Scheduled for Wednesday, May 18, 2016 at 4:30 PM EDT

South Easton, MA -- (ReleaseWire) -- 05/19/2016 -- Quarterly Products and Services Revenue Increases 26% Year/Year;

Sales of Instruments and Consumables Show Significant Increases

Q1 2016 Highlights Include Completion of Over-Subscribed $5 Million Financing

& Co-Marketing Agreement with Global Life Science Leader SCIEX

Investor Conference Call Scheduled for Wednesday, May 18, 2016 at 4:30 PM EDT

Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company") today announced financial results for the 2016 first quarter ended March 31, 2016, provided a business update, and offered limited guidance for the remainder of FY2016.

Financial Results: Q1 2016 vs. Q1 2015.  Products and services revenue was $454,350 for the first quarter of 2016 compared to $359,364 for same period in 2015, an increase of $94,986 or 26%.  Two major drivers of our product revenue growth were instrument sales, which increased 41% during the comparative quarterly periods (from $234,985 to $332,016) and consumable sales, which increased 11% (from $39,835 to $44,234).  Grant revenue decreased 31% during the comparative periods, from $80,770 in Q1 2015 to $56,128 in Q1 2016.  This decrease in grant revenue, which is expected to be short-term, allowed the Company to focus grant personnel in other critical areas during the first quarter of 2016, specifically sales/marketing and new product development.  The additional efforts in sales/marketing were partially responsible for the 16% increase reported in quarterly total revenue, from $440,134 in Q1 2015 to $510,478 in Q1 2016, despite the short-term decrease in grant revenue.

Operating loss for the quarter ended March 31, 2016 was $1,045,945 compared to a loss of $874,819 for the same period in 2015, an increase of approximately 19.6%.  This increase in operating loss was due to a large extent to increases in R&D (primarily the addition of a Ph.D. level electrical engineer and increased facility rental cost to accommodate growth), M&S expenses (primarily the costs for additional marketing and for data generation by our key collaborators), and G&A (primarily costs related to our successful fund-raising efforts), off-set partially by increases in total revenue.

Loss per common share – basic and diluted – was $0.26 for the quarter ended March 31, 2016 compared to a loss per common share – basic and diluted – of $0.11 for the same period in 2015.

Financial & Operational Highlights: Q1 2016

- Approximately $1.4M was received in a private placement of fixed-rate convertible debentures during the quarter, bringing the total raised in our $5M PIPE to an over-subscribed amount of $6.3M.

- All five members of the Company's Board of Directors participated in the final close of the Company's $5M PIPE, with a total investment from the directors of approximately $165,000.

- Q1 2015 products & services revenue increased by approximately 26% over Q1 2015.

- We added a full-time, Ph.D. level electrical engineer to our R&D staff.

- SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of the Danaher Corporation, announced that they and PBI had entered into an exclusive co-marketing agreement.

- In a report focused on the exclusive co-marketing agreement between SCIEX and PBI, Emerging Growth LLC indicated the combination of the two companies' technologies could result in superior biological insights and discoveries, and in rapid and dramatic revenue growth for PBI.

- SCIEX and Children's Medical Research Center (Sydney, Australia) announced they had joined forces to advance the promise of precision medicine. The partners stated they would benefit from SCIEX's exclusive collaborators, including PBI, and from PBI's PCT platform for increased protein quantitation and reproducibility.

- PBI participated in a SCIEX workshop on new innovations towards industrialized proteomics at the US HUPO scientific conference in Boston (March 2016), marking the first time the two companies had presented together under their co-marketing agreement.

- We completed the build of the initial working model ("breadboard") of the new Barocycler 2320EXTREME, designed primarily for use in mass spectrometry protein sample preparation, including PCT-SWATH. We also came to an arrangement with a local ISO-certified contract manufacturer, purchased sufficient parts for 30 complete units, and started the build of the first true prototype unit.

Near-Term Goals: Q2-Q4 2016

- Continue to implement a sound path toward financial self-sufficiency and future growth and profitability.

- Increase total, products & services, and grant revenues, as well as gross margins, quarter/quarter and year/year.

- Complete the manufacture of the Barocycler 2320 EXTREME and begin the commercialization phase for this robust, computer-driven, highly capable new pressure-generating instrument during Q2 2016.

- Support and expand our co-marketing program with SCIEX.

- Secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.

- Implement an expanded marketing campaign for the patent-pending micro-Pestle consumable.

- Expand sales and marketing capabilities to reach into new countries, investigators, and fields-of-use.

- Continue to prepare for a targeted up-list to NASDAQ or the NYSEMKT.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We believe the market for our pressure-based products (instruments and consumables) is large, diverse, and growing.  In order to successfully increase and expand our penetration into this market, it is essential that we continue to increase market exposure and acceptance of our novel PCT-based product line. We believe the major operational accomplishments of the 2016 first quarter – especially the co-marketing agreement with SCIEX and the development of the new Barocycler 2320EXTREME – will play key roles in increasing our visibility, acceptance, and success in penetrating this market, which will subsequently help PBI achieve rapid and dramatic growth in the near future."

Mr. Jeffrey N. Peterson, Chairman of PBI, added: "We are very pleased to have completed critical operational objectives in strategic marketing, new product development, and manufacturing during the first quarter of 2016, especially with the simultaneous achievement of key financial objectives.  We believe that 2016 is a watershed year for PBI, and are delighted to be presenting the Company with a dramatically improved financial position, growing recognition from both the investment and scientific communities, and a well-defined path towards our planned up-listing to a major stock exchange."

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Wednesday, May 18, 2016.  To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBI Q1 2016 Financial Conference Call, ID 13637901. Replay Number (877) 660-6853 (North America); (201) 612-7415 (International). Teleconference Replay Available for 30 days.

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter ended March 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click here.

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

To view the CONSOLIDATED BALANCE SHEETS please click here.

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm